Sensus Healthcare, Inc. Warrant expiring on 06/08/2020
SRTSW
SRTSW was delisted on the 4th of June, 2020.
3 hedge funds and large institutions have $15K invested in Sensus Healthcare, Inc. Warrant expiring on 06/08/2020 in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
62% less capital invested
Capital invested by funds: $39K → $15K (-$24K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$197 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19 |
SRTSW Hedge Fund Activity: Q4 2019 in Review
3 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Sensus Healthcare, Inc. Warrant expiring on 06/08/2020 (SRTSW) for Q4 2019, worth a combined $15K — down 62% from $39K a quarter earlier.
Fund positioning in SRTSW was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $197. The largest seller was UBS Group, cutting an estimated $19.
- 3 institutional investors held Sensus Healthcare, Inc. Warrant expiring on 06/08/2020 (SRTSW) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $15K of Sensus Healthcare, Inc. Warrant expiring on 06/08/2020 stock for Q4 2019, down 62% quarter-over-quarter.
- 0 funds opened new Sensus Healthcare, Inc. Warrant expiring on 06/08/2020 positions in Q4 2019 and 0 closed out.
- The largest Sensus Healthcare, Inc. Warrant expiring on 06/08/2020 buyer in Q4 2019 was Susquehanna International Group, an estimated $197 added.
- The largest Sensus Healthcare, Inc. Warrant expiring on 06/08/2020 seller in Q4 2019 was UBS Group, an estimated $19 sold.
Based on aggregated 13F filings for Q4 2019.